Introduction Nintedanib and pirfenidone reduce the rate of progression in fibrotic lung diseases. Until 2024 these medications could only be prescribed by tertiary specialist centres in England. We ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results